Department of Neurology, Third Xiangya Hospital, Central South University, Changsha, China.
Front Immunol. 2023 Dec 22;14:1269241. doi: 10.3389/fimmu.2023.1269241. eCollection 2023.
Epilepsy is a group of enduring neurological disorder characterized by spontaneous and recurrent seizures with heterogeneous etiology, clinical expression, severity, and prognosis. Growing body of research investigates that epileptic seizures are originated from neuronal synchronized and excessive electrical activity. However, the underlying molecular mechanisms of epileptogenesis have not yet been fully elucidated and 30% of epileptic patients still are resistant to the currently available pharmacological treatments with recurrent seizures throughout life. Over the past two decades years accumulated evidences provide strong support to the hypothesis that neuroinflammation, including microglia and astrocytes activation, a cascade of inflammatory mediator releasing, and peripheral immune cells infiltration from blood into brain, is associated with epileptogenesis. Meanwhile, an increasing body of preclinical researches reveal that the anti-inflammatory therapeutics targeting crucial inflammatory components are effective and promising in the treatment of epilepsy. The aim of the present study is to highlight the current understanding of the potential neuroinflammatory mechanisms in epileptogenesis and the potential therapeutic targets against epileptic seizures.
癫痫是一组以自发性和复发性癫痫发作为特征的持久神经系统疾病,其病因、临床表现、严重程度和预后存在异质性。越来越多的研究表明,癫痫发作起源于神经元同步和过度的电活动。然而,癫痫发生的潜在分子机制尚未完全阐明,30%的癫痫患者仍然对目前可用的药物治疗有反应,一生中反复发作。在过去的二十年里,大量的证据为神经炎症假说提供了有力的支持,包括小胶质细胞和星形胶质细胞的激活、一系列炎症介质的释放以及外周免疫细胞从血液渗透到大脑,与癫痫发生有关。同时,越来越多的临床前研究表明,针对关键炎症成分的抗炎治疗在癫痫治疗中是有效和有前景的。本研究的目的是强调目前对癫痫发生中潜在神经炎症机制的理解,以及针对癫痫发作的潜在治疗靶点。
Mol Neurobiol. 2022-3
Inflamm Res. 2023-4
Top Companion Anim Med. 2013-5
J Neuroinflammation. 2017-1-13
CNS Neurol Disord Drug Targets. 2020
Acta Epileptol. 2025-8-21
Front Neurol. 2025-5-30
Inflamm Res. 2023-4
Naunyn Schmiedebergs Arch Pharmacol. 2023-5
Epilepsy Res. 2022-10
Front Neurol. 2022-6-28